Shilpa Medicare, along with Zydus Group and Shorla Oncology, has obtained approval from the USFDA for IMKELDI, which is the first oral liquid formulation of imatinib. This medication is designed to treat specific types of cancer, including gastrointestinal tumors (GIST). The innovative delivery system of IMKELDI addresses the challenges of patient adherence that are associated with traditional imatinib. It provides a more convenient option for individuals who have difficulty swallowing pills or require personalized dosing.

Shilpa Medicare has reported impressive financial results for the September quarter, with a consolidated net profit increase of 28% compared to the previous quarter and a remarkable 1014% increase compared to the same period last year, amounting to Rs 18 crore. The company's revenue from operations also experienced a quarterly rise of 17.5% and a year-on-year increase of 10%, reaching Rs 344 crore. Shilpa Medicare has consistently demonstrated growth, achieving eight consecutive quarters of sequential improvement in EBITDA.

The success of IMKELDI and the positive financial performance of Shilpa Medicare highlight the company's commitment to innovation and growth in the field of cancer treatment. With the approval of the first oral liquid formulation of imatinib, patients with gastrointestinal tumors now have a more convenient and personalized option for their medication. This development not only addresses the challenges of patient adherence but also demonstrates the company's dedication to improving the lives of individuals affected by cancer.